KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Capital Employed (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Return on Capital Employed for 14 consecutive years, with 0.06% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 13.0% to 0.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.06%, a 13.0% decrease, with the full-year FY2025 number at 0.06%, down 14.0% from a year prior.
  • Return on Capital Employed was 0.06% for Q4 2025 at Supernus Pharmaceuticals, down from 0.08% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.12% in Q1 2021 to a low of 0.06% in Q4 2025.
  • A 5-year average of 0.03% and a median of 0.05% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: grew 8bps in 2024, then dropped -13bps in 2025.
  • Supernus Pharmaceuticals' Return on Capital Employed stood at 0.07% in 2021, then crashed by -31bps to 0.05% in 2022, then plummeted by -112bps to 0.01% in 2023, then surged by 1545bps to 0.08% in 2024, then plummeted by -174bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Return on Capital Employed are 0.06% (Q4 2025), 0.08% (Q4 2024), and 0.03% (Q2 2024).